Acadian Asset Management
AKBA icon

Acadian Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Acadian Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91M Sell
1,377,068
-822,679
-37% -$1.13M ﹤0.01% 975
2025
Q4 		$3.54M Buy
2,199,747
+51,796
+2% +$108K 0.01% 741
2025
Q3 		$5.86M Buy
2,147,951
+797,766
+59% +$2.65M 0.01% 609
2025
Q2 		$4.91M Buy
+1,350,185
New +$3.71M 0.01% 589
2024
Q3 		– Sell
-4,063,383
Closed -$4.14M – 2062
2024
Q2 		$4.14M Sell
4,063,383
-1,246,372
-23% -$1.54M 0.01% 547
2024
Q1 		$9.71M Sell
5,309,755
-1,605,748
-23% -$2.57M 0.03% 309
2023
Q4 		$8.57M Sell
6,915,503
-307,985
-4% -$314K 0.03% 326
2023
Q3 		$8.23M Sell
7,223,488
-236,865
-3% -$304K 0.03% 323
2023
Q2 		$6.82M Sell
7,460,353
-22,700
-0.3% -$21.9K 0.03% 375
2023
Q1 		$4.19M Hold
7,483,053
– – 0.02% 505
2022
Q4 		$4.32M Hold
7,483,053
– – 0.02% 483
2022
Q3 		$2.37M Buy
7,483,053
+144,010
+2% +$56.5K 0.01% 586
2022
Q2 		$2.59M Buy
+7,339,043
New +$3.08M 0.01% 568
2021
Q3 		– Sell
-10,636
Closed -$40K – 1698
2021
Q2 		$40K Buy
10,636
+8,536
+406% +$28.7K ﹤0.01% 1831
2021
Q1 		$7K Sell
2,100
-833,985
-100% -$3M ﹤0.01% 2016
2020
Q4 		$2.34M Buy
836,085
+116,768
+16% +$341K 0.01% 717
2020
Q3 		$1.8M Buy
719,317
+715,611
+19,310% +$6.28M 0.01% 698
2020
Q2 		$50K Buy
+3,706
New +$38.3K ﹤0.01% 1917
2018
Q4 		– Sell
-73,516
Closed -$649K – 1710
2018
Q3 		$649K Sell
73,516
-27,158
-27% -$243K ﹤0.01% 829
2018
Q2 		$1M Sell
100,674
-199,758
-66% -$2M ﹤0.01% 727
2018
Q1 		$2.86M Sell
300,432
-324,735
-52% -$4.54M 0.01% 519
2017
Q4 		$9.3M Sell
625,167
-103,062
-14% -$1.71M 0.04% 289
2017
Q3 		$14.3M Buy
728,229
+357,491
+96% +$5.5M 0.06% 237
2017
Q2 		$5.33M Buy
370,738
+74,179
+25% +$940K 0.02% 383
2017
Q1 		$2.73M Buy
+296,559
New +$2.9M 0.01% 543

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management's AKBA Position: Q1 2026 in Review

Acadian Asset Management reduced its Akebia Therapeutics (AKBA) stake by 37% in Q1 2026, selling an estimated $1.13M and leaving 1,377,068 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #975.

Acadian Asset Management first reported a position in AKBA in Q1 2017 and has held it in 25 quarters since. The position peaked at $14.3M in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Acadian Asset Management held 1,377,068 shares of Akebia Therapeutics worth $1.91M as of Q1 2026.
  • Acadian Asset Management sold 822,679 Akebia Therapeutics shares in Q1 2026, an estimated $1.13M.
  • Akebia Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #975 holding.
  • Acadian Asset Management first reported a position in Akebia Therapeutics in Q1 2017 and has held it in 25 quarters since.
  • Acadian Asset Management's Akebia Therapeutics position peaked at $14.3M in Q3 2017.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.